title: Synergistic effects of Akt1 shRNA and paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel on breast cancer.
abstract: The phosphoinositide 3-kinase/Akt1 signaling pathway has emerged as a target for cancer therapy. In this study, we aimed to develop a strategy to enhance Akt-targeted cancer therapy. We hypothesized that combination of Akt1-targeted therapy with conventional chemotherapy using paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel may have synergistic effects in cancer therapeutic efficiency compared with chemotherapy alone. In this study, we found that the combination of shAkt1 with paclitaxel exerted synergistic anti-cancer effects, thus, inhibiting the growth of human breast cancer cells, and breast cancer xenografts in mice as well. The combination therapy demonstrated enhanced anti-cancer effects through inhibiting Akt1 signaling and inducing apoptosis. Our results suggest that the presented strategy of combination of shAkt1 with paclitaxel may have a potential for treatment of breast cancer.
authors.affiliation: Department of Agricultural Biotechnology and Research Institute for Agriculture and Life Sciences, Seoul National University, Seoul 151 921, Republic of Korea.
authors.forename: Ding-Ding
authors.initials: DD
authors.lastname: Guo
authors.forename: Seong-Ho
authors.initials: SH
authors.lastname: Hong
authors.forename: Hu-Lin
authors.initials: HL
authors.lastname: Jiang
authors.forename: Ji-Hye
authors.initials: JH
authors.lastname: Kim
authors.forename: Arash
authors.initials: A
authors.lastname: Minai-Tehrani
authors.forename: Ji-Eun
authors.initials: JE
authors.lastname: Kim
authors.forename: Ji-Young
authors.initials: JY
authors.lastname: Shin
authors.forename: Tao
authors.initials: T
authors.lastname: Jiang
authors.forename: You-Kyoung
authors.initials: YK
authors.lastname: Kim
authors.forename: Yun-Jaie
authors.initials: YJ
authors.lastname: Choi
authors.forename: Chong-Su
authors.initials: CS
authors.lastname: Cho
authors.forename: Myung-Haing
authors.initials: MH
authors.lastname: Cho
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor / Q000187:drug effects; D005260:Female; D006801:Humans; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate / Q000737:chemistry* / Q000378:metabolism; D044243:Linoleic Acids, Conjugated / Q000737:chemistry* / Q000378:metabolism; D008422:Materials Testing; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D017239:Paclitaxel / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D020442:Poloxamer / Q000737:chemistry* / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000235:genetics* / Q000378:metabolism; D034741:RNA, Small Interfering / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents; D044243:Linoleic Acids, Conjugated; D034741:RNA, Small Interfering; D020442:Poloxamer; D020136:Hydrogel, Polyethylene Glycol Dimethacrylate; D051057:Proto-Oncogene Proteins c-akt; D017239:Paclitaxel